Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 181

The DOI matches its Crossref record.

Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life.

Noonan, M, Chervinsky, P, Busse, W W, Weisberg, S C, Pinnas, J, de Boisblanc, B P, Boltansky, H, Pearlman, D, Repsher, L, Kellerman, D · 1995 · American Journal of Respiratory and Critical Care Medicine

Abstract

This study examined the ability of fluticasone propionate aerosol to reduce oral prednisone requirements in patients with severe asthma. Ninety-six patients dependent on oral prednisone were treated for 16 wk with placebo or fluticasone propionate aerosol (750 or 1,000 micrograms twice daily). Their dosage of oral prednisone was adjusted weekly according to predetermined criteria. A total of 69% and 88% of patients treated with fluticasone propionate 750 and 1,000 micrograms twice daily, respectively, compared with 3% of placebo-treated patients used no prednisone by the end of the study. In the fluticasone propionate groups, FEV1 and peak expiratory flow rates at the last evaluable visit/date improved and the number of night awakenings and symptomatic albuterol use declined relative to placebo values (p < 0.05). Patient-rated asthma symptoms improved in the groups receiving fluticasone propionate but not in the placebo group (p < 0.005). Fluticasone propionate aerosol was well-tolerated, and it improved some dimensions of health-related quality of life measured using a standard patient survey. Fluticasone propionate aerosol (750 or 1,000 micrograms twice daily) effectively and safely allowed most asthmatics dependent on oral corticosteroids to reduce or eliminate oral prednisone use while improving pulmonary function and quality of life.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/ajrccm.152.5.7582278

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 181

Metadata

Authors
Noonan, M., Chervinsky, P., Busse, W. W., Weisberg, S. C., Pinnas, J., de Boisblanc, B. P., Boltansky, H., Pearlman, D., Repsher, L., & Kellerman, D.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
1995-11
Volume
152
Issue
5
Pages
1467-1473
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2051146255
Cited by
181
References
0
FWCI
11.40
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. https://app.cochat.ai/papers/10.1164/ajrccm.152.5.7582278
The paper
Noonan, M., Chervinsky, P., Busse, W. W., Weisberg, S. C., Pinnas, J., de Boisblanc, B. P., Boltansky, H., Pearlman, D., Repsher, L., & Kellerman, D. (1995). Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/ajrccm.152.5.7582278

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.